The "Checkpoint Inhibitor Refractory Cancer Drugs Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added to the Credence Research Inc. offering.

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

ANI Pharmaceuticals (NASDAQ:ANIP) executives used a presentation at the Leerink Partners Global Healthcare Conference to outline the company’s recent performance, 2026 financial outlook, and ...

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro), both from Janssen Biotech, Inc, marks a significant shift in treating ...

C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. Click for my latest analysis of CCCC stock.

Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs ...

Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Q4 2025 Earnings Conference Call. [Operator Instructions] I will now turn the call over to Nicole Riley, Head of Investor ...

The Imugene share price is plunging after announcing a heavily discounted capital raising. The post Why this ASX healthcare stock has crashed 20% today appeared first on The Motley Fool Australia.

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with ...

Radiomics extracts quantitative data from medical images, but its role in predicting deterioration after traumatic brain ...